NCT00607581View on ClinicalTrials.gov

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions
Amyloidosis
Interventions
DRUG

cyclophosphamide

cyclophosphamide: 500 mg orally on days 1, 8, 15

DRUG

lenalidomide

lenalidomide: 15 mg orally on days 1-21

DRUG

dexamethasone

dexamethasone: 40 mg orally on days on days 1, 8, 15, 22

Trial Locations (1)

27100

Amyloidosis Research and Treatment Center - Fondazione IRCCS Policlinico San Matteo, Pavia

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER